An elemental analysis system includes a reactor having at least one reduction reaction zone including a metal zeolite that can reduce nitrogen oxides (NO.sub.x) to molecular nitrogen (N.sub.2) by selective catalytic reduction. Correspondingly, a method of elemental analysis includes providing a reactor having at least one reduction reaction zone including a metal zeolite and reducing nitrogen oxides (NO.sub.x) to molecular nitrogen (N.sub.2) by selective catalytic reaction on the metal zeolite.

An elemental analysis system includes a reactor having at least one reduction reaction zone including a metal zeolite that can reduce nitrogen oxides (NO.sub.x) to molecular nitrogen (N.sub.2) by selective catalytic reduction. Correspondingly, a method of elemental analysis includes providing a reactor having at least one reduction reaction zone including a metal zeolite and reducing nitrogen oxides (NO.sub.x) to molecular nitrogen (N.sub.2) by selective catalytic reaction on the metal zeolite.

The present invention relates to a chromatography system and a method therefor. The chromatography system comprising an inlet port (102) for receiving a sample, an outlet port (106) for delivering the sample, a detector (201), a column (104), and a valve (202) in fluid communication with the inlet port, the outlet port, the detector, and the column. The valve (202) comprises a first position (304) wherein the inlet port is in fluid communication with the outlet port via a first fluid path comprising the detector and the column, wherein the detector is arranged upstream the column. The valve comprises a second position (404) wherein the inlet port is in fluid communication with the outlet port via a second fluid path comprising the detector and the column, wherein the detector is arranged downstream the column.

The present invention relates to a disease-specific metabolite profile, and particularly to a biomarker composition obtained by screening from urine-specific metabolite profiles of coronary heart disease subjects. The present invention also relates to a use of the biomarker compositions in risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease, and to a method for risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease. The biomarker composition as provided by the present invention can be used for early diagnosis of coronary heart disease and has high sensitivity, good specificity and good application prospects.

A supercritical fluid chromatography system comprises a first pump for pumping a first flow stream comprising a compressible fluid and a second pump for pumping a second flow stream comprising a modifier fluid. The second pump is in parallel with the first pump. A column is located in a combined flow stream. The column is located downstream of the first and second pumps. The combined flow stream comprises the first flow stream, the second flow stream, and a sample. A detector is located downstream of the column. A gas-liquid separator is located downstream of the detector. The gas-liquid separator is configured to vent a majority of the compressible fluid while maintaining a majority of the sample, thus preventing aerosolization of the flow stream and minimizing sample loss as well as cross contamination. An open bed collector is located after the gas-liquid separator.

A concentration sensor for at least one given gas comprising at least one suspended structure (2) with respect to a support, said suspended structure (2) being of an electrically conductive material and said structure having a low heat response time, means for biasing said suspended element (2) and means (8) for measuring the variation of the electric voltage at the terminals of the suspended structure (2), the biasing means (6) being formed by an alternating current source the intensity of which heats the suspended structure (2) and the frequency of which gives rise to a phase shift between a signal of the biasing means and a signal measured by the measuring means, and means for determining a phase shift variation due to a gas concentration variation and means for determining the concentration variation of said gas from the phase variation.

A concentration sensor for at least one given gas comprising at least one suspended structure (2) with respect to a support, said suspended structure (2) being of an electrically conductive material and said structure having a low heat response time, means for biasing said suspended element (2) and means (8) for measuring the variation of the electric voltage at the terminals of the suspended structure (2), the biasing means (6) being formed by an alternating current source the intensity of which heats the suspended structure (2) and the frequency of which gives rise to a phase shift between a signal of the biasing means and a signal measured by the measuring means, and means for determining a phase shift variation due to a gas concentration variation and means for determining the concentration variation of said gas from the phase variation.

An analysis apparatus includes an extraction unit that extracts a baseline portion from chromatographic data that is acquired from an apparatus, and a determination unit that determines a normality in the apparatus based on normal chromatographic data and a feature of the baseline portion of the chromatographic data extracted by the extraction unit.

An analysis apparatus includes an extraction unit that extracts a baseline portion from chromatographic data that is acquired from an apparatus, and a determination unit that determines a normality in the apparatus based on normal chromatographic data and a feature of the baseline portion of the chromatographic data extracted by the extraction unit.

The present invention relates to a disease-specific metabolite profile, and particularly to a biomarker composition obtained by screening from blood plasma-specific profiles of coronary heart disease subjects. The present invention also relates to a use of the biomarker compositions in risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease, and to a method for risk assessment, diagnosis, early diagnosis, or pathological staging of coronary heart disease. The biomarker composition as provided by the present invention can be used for early diagnosis of coronary heart disease and has high sensitivity, good specificity and good application prospects.